<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320476</url>
  </required_header>
  <id_info>
    <org_study_id>KMM52</org_study_id>
    <secondary_id>26866138MMY2027</secondary_id>
    <nct_id>NCT00320476</nct_id>
  </id_info>
  <brief_title>VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates</brief_title>
  <official_title>Velcade®, Thalidomide, Dexamethasone (VTD) Induction Therapy Followed By Melphalan, Prednisone, Thalidomide (MPT) Maintenance As a First Line Treatment For The Patients With Multiple Myeloma Who Are Non-Transplant Candidates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korean Multiple Myeloma Working Party</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korean Multiple Myeloma Working Party</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple Myeloma is a incurable disease. Recently developed targeted therapy gave new hope&#xD;
      for the patients with multiple myeloma. Velcade in combination with other agents are&#xD;
      currently in trials for the newly diagnosed patient, we designed sequential treatment with&#xD;
      VTD and MPT for the patients who are not transplant candidates. This would be expected to&#xD;
      result in maximal tumor control, and thus, in maximal survival benefit, equivalent to high&#xD;
      dose therapy with autologous transplantation in younger population&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The two effective and non-cross resistant regimens, VTD and MPT, will be applied sequentially&#xD;
      to the patients with multiple myeloma who are not transplant candidates. This would be&#xD;
      expected to result in maximal tumor control, and thus, in maximal survival benefit,&#xD;
      equivalent to high dose therapy with autologous transplantation in younger population&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate of VTD induction Therapy</measure>
    <time_frame>2008-02-01</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate of VTD/MPT maintenance therapy</measure>
    <time_frame>2008-02-01</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival Overall survival of VTD/MPT</measure>
    <time_frame>2008-02-01</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate toxicities of VTD/MPT</measure>
    <time_frame>2008-02-01</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">35</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed patients with overt multiple myeloma who are not candidates for&#xD;
             HDT/SCT because of old age (&gt; 65) or presence of comorbid conditions likely to have a&#xD;
             negative impact on tolerability of HDT/SCT. Sponsors review this conditions and&#xD;
             approval is required.&#xD;
&#xD;
          -  Presence of measurable disease : serum M-protein &gt; 1g/dL or urine M- protein &gt;&#xD;
             400mg/day&#xD;
&#xD;
          -  Performance status £ ECOG 2&#xD;
&#xD;
          -  Expected survival ³ 6 months&#xD;
&#xD;
          -  Pretreatment clinical laboratory values meeting the following criteria within 14 days&#xD;
             before enrollment platelet ≥ 100 x 109/L hemoglobin ≥ 8 g/dL (≥ 4.96 mol/L) Prior RBC&#xD;
             transfusion or recombinant human erythropoietin use is allowed) absolute neutrophil&#xD;
             count (ANC) ≥ 1.0 x 109/L aspartate aminotransferase (AST) ≤ 2.5 times the upper limit&#xD;
             of normal alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal total&#xD;
             bilirubin ≤ 1.5 times the upper limit of normal serum creatinine ≤ 3mg/dL corrected&#xD;
             serum calcium &lt;14 mg/dL (&lt;3.5 mmol/L)&#xD;
&#xD;
          -  Subjects (or their legally acceptable representatives) must have signed an informed&#xD;
             consent document indicating that they understand the purpose of and procedures&#xD;
             required for the study and are willing to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoldering or indolent myeloma&#xD;
&#xD;
          -  History of allergic reaction attributable to compounds containing boron or mannitol&#xD;
&#xD;
          -  Known hypersensitivity to thalidomide or dexamethasone&#xD;
&#xD;
          -  Peripheral neuropathy or neuropathic pain Grade 2 or higher as defined by NCI CTCAE&#xD;
             version 3&#xD;
&#xD;
          -  Uncontrolled or severe cardiovascular disease, including MI within 6 months of&#xD;
             enrolment, New York Heart Association (NYHA) Class III or IV heart failure,&#xD;
             uncontrolled angina, clinically significant pericardial disease, or cardiac&#xD;
             amyloidosis, cardiac ejection fraction &lt;0.5 : Severe conduction disorder : Hypotension&#xD;
             (sitting systolic BP ≤ 100 mmHg and/or sitting diastolic BP ≤ 60 mmHg&#xD;
&#xD;
          -  Sepsis&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Uncontrolled Diabetes Mellitus&#xD;
&#xD;
          -  Recurrent DVT or pulmonary embolism&#xD;
&#xD;
          -  Active ulcers detected by gastroscopy&#xD;
&#xD;
          -  Serious medical or psychiatric illness likely to interfere with participation in this&#xD;
             clinical study.&#xD;
&#xD;
          -  Receipt of extensive radiation therapy within 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Hoon Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Inchon</city>
        <zip>405-220</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2006</verification_date>
  <study_first_submitted>April 27, 2006</study_first_submitted>
  <study_first_submitted_qc>May 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2006</study_first_posted>
  <last_update_submitted>May 5, 2008</last_update_submitted>
  <last_update_submitted_qc>May 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>Lee M.D.</name_title>
    <organization>korean Multiple Myeloma Working Party</organization>
  </responsible_party>
  <keyword>Multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

